TD Asset Management Inc Sells 301,373 Shares of Catalent, Inc. (NYSE:CTLT)

TD Asset Management Inc decreased its stake in Catalent, Inc. (NYSE:CTLT) by 86.0% during the 2nd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 48,983 shares of the company’s stock after selling 301,373 shares during the period. TD Asset Management Inc’s holdings in Catalent were worth $2,754,000 as of its most recent filing with the SEC.

Other hedge funds have also added to or reduced their stakes in the company. Lindbrook Capital LLC raised its position in Catalent by 79.4% in the first quarter. Lindbrook Capital LLC now owns 470 shares of the company’s stock worth $27,000 after acquiring an additional 208 shares during the period. Thurston Springer Miller Herd & Titak Inc. bought a new stake in Catalent in the second quarter worth about $42,000. Mather Group LLC. bought a new stake in Catalent in the first quarter worth about $52,000. Principal Securities Inc. bought a new stake in Catalent in the fourth quarter worth about $56,000. Finally, GAMMA Investing LLC raised its position in Catalent by 25.9% in the second quarter. GAMMA Investing LLC now owns 1,032 shares of the company’s stock worth $58,000 after acquiring an additional 212 shares during the period.

Insiders Place Their Bets

In other news, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total value of $39,428.72. Following the completion of the sale, the insider now owns 29,974 shares of the company’s stock, valued at approximately $1,785,251.44. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, SVP Scott Gunther sold 666 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.55, for a total transaction of $39,660.30. Following the completion of the sale, the senior vice president now directly owns 39,635 shares in the company, valued at approximately $2,360,264.25. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Ricky Hopson sold 662 shares of the company’s stock in a transaction on Friday, August 2nd. The shares were sold at an average price of $59.56, for a total transaction of $39,428.72. Following the sale, the insider now owns 29,974 shares of the company’s stock, valued at $1,785,251.44. The disclosure for this sale can be found here. Insiders sold a total of 13,409 shares of company stock valued at $782,923 in the last quarter. Corporate insiders own 0.31% of the company’s stock.

Catalent Price Performance

CTLT stock opened at $59.69 on Friday. The company has a debt-to-equity ratio of 1.37, a current ratio of 2.51 and a quick ratio of 1.77. Catalent, Inc. has a one year low of $31.80 and a one year high of $61.20. The stock has a market cap of $10.80 billion, a PE ratio of -9.79, a P/E/G ratio of 2.14 and a beta of 1.15. The firm has a 50 day simple moving average of $59.09 and a two-hundred day simple moving average of $57.09.

Analysts Set New Price Targets

Several research firms have recently issued reports on CTLT. StockNews.com began coverage on shares of Catalent in a research report on Tuesday. They issued a “sell” rating on the stock. Royal Bank of Canada reissued a “sector perform” rating and issued a $63.50 price target on shares of Catalent in a research report on Thursday, July 11th. Barclays boosted their price target on shares of Catalent from $47.00 to $63.00 and gave the company an “equal weight” rating in a research report on Friday, June 28th. Finally, William Blair reissued a “market perform” rating on shares of Catalent in a research report on Tuesday, September 3rd. One research analyst has rated the stock with a sell rating, six have issued a hold rating and one has issued a buy rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Hold” and an average price target of $58.08.

Catalent Company Profile

Catalent, Inc, together with its subsidiaries, develops and manufactures solutions for drugs, protein-based biologics, cell and gene therapies, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies; pDNA, iPSCs, oncolytic viruses, and vaccines; formulation, development, and manufacturing for parenteral dose forms, including vials, prefilled syringes, and cartridges; and analytical development and testing services for large molecules.